Dr Anirvan Ghosh named head of discovery for CNS at Roche
This article was originally published in Scrip
Roche has named Dr Anirvan Ghosh head of discovery for central nervous system (CNS). He will oversee discovery research in the CNS Disease and Translational Area with an emphasis on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression and neurodevelopment disorders. Dr Ghosh, who will relocate to Basel, Switzerland, joins Roche's Pharma Research and Early Development organisation from the University of California San Diego, where he has been the Stephen Kuffler professor of neurobiology since 2003; chair of the neurobiology section, division of biological sciences, since 2008; and co-director of the Center for Neural Circuits and Behavior since 2009.
You may also be interested in...
The Japan-headquartered drugmaker says there is a need for affordable oral treatment options on top of currently available lipid-lowering therapies and the two drugs it licensed from Esperion can meet that need.
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.